Profile
MiddleBrook Pharmaceuticals, Inc. (Nasdaq: MBRK) is a pharmaceutical company focused on developing and commercializing products that fulfill unmet medical needs. MiddleBrook currently markets KEFLEX, the immediate-release brand of cephalexin, and MOXATAG—the first and only FDA-approved once-daily amoxicillin.

We have developed a proprietary delivery technology called PULSYS, which enables the pulsatile delivery, or delivery in rapid bursts, of certain drugs. MOXATAG is our first product utilizing our proprietary PULSYS technology. While MiddleBrook is currently focused on the anti-infective arena, we see opportunities for PULSYS products in the anti-fungal, antiviral, and oncology markets as well.

Featured Documents

   MBRK Corporate Overview Presentation 12-21-09

   Third Quarter 2009 Results Conference Call Slides

   Corporate Fact Sheet

   Annual Report on Form 10-K

   2008 Annual Report

Recent Releases

Jan 5, 2010
MiddleBrook Pharmaceuticals Reports Inducement Grants Under NASDAQ Marketplace Rule 4350

Dec 3, 2009
MiddleBrook Pharmaceuticals Reduces Field Sales Force and Corporate Staff, Receives Notice from Nasdaq Regarding Minimum Bid Price Requirement

View all releases »

Stock Chart
3 Mo.   6 Mo.   1 Yr.
Stock Quote
MiddleBrook Pharmaceuticals, Inc.
Price:	0.49
Change:	+ 0.02
Day High:	0.58
Day Low:	0.47
Volume:	884,700
Delayed at least 20 minutes. Provided by eSignal.

Contact Information

Faith Pomeroy-Ward
Associate Vice President,
Investor & Corporate Relations
MiddleBrook Pharmaceuticals
7 Village Circle, Suite 100
Westlake, TX 76262
Phone: (817) 837-1208
Fax: (817) 582-0400
faith@middlebrookpharma.com